# Partners. Shared Commitment. What Comes Next. | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/399035
- Entity ID: wefunder:feed_item:399035
- Published at: 2026-10-02 13:55:59 UTC
- Updated at: 2026-10-02 17:03:05 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen-Jam Investors,We believe that resolving inflammation will lead to longer, healthier, more resilient lives.Your investments have helped turn that belief into clinical evidence, an expanding intellectual-property portfolio, manufacturing capabilities, a pipeline of therapeutics, and a clearer path forward for SJP-001.They have also helped Sen-Jam build strategic partnerships with experienced organizations willing to contribute far more than services.Experienced partners working alongside usKVK-Tech has committed $8 million to our manufacturing partnership. KVK brings decades of pharmaceutical-manufacturing experience, technical know-how, established capabilities, and the capacity to help us manufacture and ultimately scale our therapeutics.Under our existing agreement, TASK Clinical committed to fund two-thirds of the SJP-001 Phase 3 study, up to $5 million, through clinical services provided in exchange for Sen-Jam equity.We have now agreed to bring $566,000 of that commitment forward to fund one-third of the Phase 2b study. The equity exchange will be calculated using a $300 million valuation basis. We expect to execute the addendum formalizing this arrangement next week.Following execution, approximately $4.4 million of TASK’s original commitment would remain available for Phase 3.The economics are meaningful, but they tell only part of the story. TASK and KVK bring years of experience, know-how, people, judgment, execution capabilities, and confidence in what we are building.They are not simply providing services. They are strategic partners helping us bring important medicines to patients.Why the current offering mattersOur bridge round is scheduled to close on October 15. We have raised approximately $300,000 toward our $1 million goal, leaving $700,000 to complete the round.The current offering has a $150 million valuation cap. Based on our current plan, we presently expect our next $4 million offering to be conducted at approximately a $300 million valuation, subject to final approval, documentation, and market conditions.Put plainly: assuming comparable terms and capitalization, each dollar invested under the current $150 million cap has approximately twice the potential purchasing power for equity as a dollar invested at a $300 million valuation.October 15 is therefore the final planned opportunity to participate under the current offering’s terms.Actual ownership will depend on the securities offered, conversion provisions, accrued interest, capitalization, dilution, and future financing terms. This comparison illustrates the difference between the two valuation levels and does not promise any particular ownership or return.What completing this round can unlockFunding from this bridge will help Sen-Jam: Advance the SJP-001 Phase 2b trial ($150M -> $300M) Advance Atlas toward external proof and validation. Expand and protect our priority intellectual property. Pursue licensing and business-development opportunities. Build momentum toward our planned $4 million financing. This is how we bring together the science, strategic partnerships, and execution required to create the next stage of value.Hear directly from our strategic partnersPlease join us on Thursday, October 8 at 11:00 a.m. ET for:In Good Company: The Partners Powering Sen-Jam’s Next ChapterJohann de Bruyn, CEO of TASK Clinical, and Kiran Vepuri, EVP of Business Development and Brand Marketing at KVK-Tech, will join the Sen-Jam executive team.You will hear directly from them about why they chose to work with Sen-Jam, what they bring to these relationships, and how we are working together to move SJP-001 and the broader company forward.Register for the investor briefingIf you are eligible to participate, I invite you to consider an additional investment before the October 15 close.Invest in the current offeringOr schedule a conversation with me, ask your questions, and decide whether this opportunity is right for you.You helped us build something important. Now experienced strategic partners are bringing their capabilities alongside ours. Together, we have an opportunity to unlock what comes next.With gratitude and confidence,JimThis communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase securities. Any offering will be made only to eligible investors through the applicable offering documents, which should be reviewed carefully before making an investment decision. Forward-looking statements involve risks and uncertainties, and actual results may differ materially.